LUCIUS 卢修斯 色瑞替尼 Ceritinib非小细胞肺癌
LUCIUS 卢修斯 色瑞替尼 Ceritinib非小细胞肺癌
色瑞替尼
美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品
Ceritinib
老挝国家食药监局批准上市
老挝国家药检所检测认证
Composition:
Each capsule contains Ceritinib ....... 150mg.
Indication:
LUCIUS
非小细胞肺癌
LuciCer is a kinase inhibitor indicated for the
PHARMACEUTICALS
treatment of patients with metastatic non-
small cell lung cancer (NSCLC) whose
tumors are anaplastic lympnoma kinasc
(ALK)-positive as detected by an FDA
LuciCer
approveu les
130 mg orally once daily. Take LuciCer at
least I hour before or at least 2 hours after a
Ceritinib Capsules
Storage: in a dry place and store at 20°C to
150mg
FDA批准
25°C
Warning:
Keep medicine out of reach of Children. Do
50 Capsules
notadminister LuciCer during Pregnancy
andloustian
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by
LUCIUS
权威认证
Thongmang village, Xaythany districl.
Vientianc Capital, Laos
www.lueins
Warning : Tobe sold by retail on prescriplion
of registered puysicians only, and as directe
Rx Only
口碑质量
适应症:
适用于经FDA批准的检测方法检测为间变性淋巴瘤
激酶(ALK)呈阳性的转移性非小细胞肺癌
(NSCLC)患者的治疗。
推荐剂量:
每日一次,每次450mg,随餐服用。
无法加载取货服务可用情况
99999 件存货
查看完整详细信息